BIOMERIEUX/ FR0013280286 /
08.11.2024 15:30:19 | Изменение +0.80 | Объем сделки | Бид17:30:00 | Предложение17:30:00 | Рыночная капитализация | Дивидендная доходность | Коэффициент Цена/Доход |
---|---|---|---|---|---|---|---|
101.60EUR | +0.79% | 0 Оборот: - |
-Величина цены спроса: - | -Величина цены предложения: - | 12.11 млрдEUR | 0.83% | 33.76 |
GlobeNewswire
03.06
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in P...
GlobeNewswire
18.04
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...
GlobeNewswire
04.12.2023
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire
20.09.2023
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire
04.10.2021
Quotient Limited Announces Appointment of New Chief Scientific & Medical Officer
GlobeNewswire
16.09.2021
Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
GlobeNewswire
01.06.2021
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Upd...
GlobeNewswire
10.03.2021
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
GlobeNewswire
04.01.2021
Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass.
GlobeNewswire
07.12.2020
Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff
GlobeNewswire
17.09.2020
Victory Square Provides Corporate Update on the Strong Performance of Portfolio Companies
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница